BioNTech is trading 4.1% down at $99.55 after BMO Capital downgraded shares from Outperform to Market Perform and cut its price target from $128 to $105, citing weaker global COVID-19 vaccine demand and German inventory drawdowns.
- Broader risk-off sentiment is adding pressure, with the Dow down 1.11%; investors remain focused on interest-rate expectations and upcoming inflation data.
- The earlier colorectal-cancer trial termination and reduced 2026 revenue guidance remain additional pipeline and revenue concerns.